RecruitingPhase 1NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SystImmune Inc.
- Principal Investigator
- Rishi JainSystImmune Inc.
- Intervention
- BL-M14D1(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18-85 years · All sexes
- Timeline
- 2025 – 2027
Study locations (20)
- Valkyrie Clinical Trials, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center), San Francisco, California, United States
- University of Colorado - Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Emory Winship, Atlanta, Georgia, United States
- University of Kentucky - Markey Cancer Center, Lexington, Kentucky, United States
- John Theurer Cancer Center-Hackensack, Hackensack, New Jersey, United States
- Rutgers Cancer Institute, New Brunswick, New Jersey, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Ohio State University, Columbus, Ohio, United States
- Providence Cancer Institute, Portland, Oregon, United States
- Prisma Health Cancer Institute, Greenville, South Carolina, United States
- NEXT Dallas, Dallas, Texas, United States
- START Dallas- Fort Worth, Dallas, Texas, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07080242 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison
- RECRUITINGPHASE1, PHASE2NCT05896839Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerNational Cancer Institute (NCI)